Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

iatrogenic acute kidney injury in high risk patients, we strongly recommend that appropriate criteria are applied in future clinical trials. Furthermore, studying the effect of dapagliflozin using biomarkers of glomerular and tubular injury would add granularity to the functional criteria (serum creatinine elevation or urine output decline).[6] We strongly suggest that full KDIGO criteria be used (possibly with the inclusion of biomarkers of kidney damage) in upcoming investigations.

Published Online December 15, 2021 https://doi.org/10.1016/S2213-8587(21)00326-0

TR received consulting fees from Baxter and Contatti Medical (CytoSorbents) and payment or honoraria from AstraZeneca, Baxter, Contatti Medical (CytoSorbents), B Braun, Jafron, and Eurofarma. MO received lecture fees to their institution from bioMérieux, Fresenius Medical, and Baxter, and payment to their institution for participation on the advisory board for NxStage. AZ received grants from Baxter, bioMérieux, consulting fees from Guard Therapeutics, AM Pharma, and Piaon, payment or honoraria from Fresenius, Baxter, and bioMérieux, payment for participation in advisory boards for Guard Therapeutics, AM Pharma, and Fresenius, and payment for leadership on boards for ESAIC, A&A, and Anästhesist. JAK received grants or contracts, consulting fees, and payment or honoraria from Astute Medical/bioMérieux. CR received consulting fees and payment or honoria from ASAHI, Baxter, bioMérieux, B. Braun, CytoSorbents, ESTOR, Fresenius Medical Care, General Electric, Medtronic, and Toray.

*Thiago Reis, Marlies Ostermann, Alexander Zarbock, John A Kellum, *Claudio Ronco*

claudio.ronco@unipd.it

Laboratory of Molecular Pharmacology, Faculty of Health Sciences, University of Brasília, Asa Norte, Brasília, Brazil (TR); Department of Kidney Transplantation, Clínica de Doenças Renais de Brasília—DF STAR Hospital, Brasília, Brazil (TR); Department of Critical Care and Nephrology, King's College London, Guy's and St Thomas' Hospital, London UK (MO); Department of Anesthesiology, Intensive Care Medicine and Pain Medicine, University Hospital Münster, Münster, Germany (AZ); Center for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburg, Pittsburg, PA, USA (JAK); Department of Medicine, Università degli Studi di Padova, 35128 Padua, Italy (CR); Department of Nephrology, Dialysis and Kidney Transplantation, San Bortolo Hospital, International Renal Research Institute of Vicenza, Vicenza, Italy (CR)

1 Kosiborod MN, Esterline R, Furtado RHM, et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Diabetes Endocrinol* 2021; **9:** 586–94.

2 Ronco C, Bellomo R, Kellum JA. Acute kidney injury. *Lancet* 2019; **394:** 1949–64.

3 Chan L, Chaudhary K, Saha A, et al. AKI in hospitalized patients with COVID-19. *J Am Soc Nephrol* 2021; **32:** 151–60.

4 Heerspink HJL, Karasik A, Thuresson M, et al. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. *Lancet Diabetes Endocrinol* 2020; **8:** 27–35.

5 Procaccini FL, Alcázar Arroyo R, Albalate Ramón M, et al. Acute kidney injury in 3182 patients admitted with COVID-19: a single-center, retrospective, case-control study. *Clin Kidney J* 2021; **14:** 1557–69.

6 Ostermann M, Zarbock A, Goldstein S, et al. Recommendations on acute kidney injury biomarkers from the acute disease quality initiative consensus conference: a consensus statement. *JAMA Netw Open* 2020; **3:** e2019209.

Authors' reply

We appreciate the correspondence from Thiago Reis and colleagues regarding the selection of criteria for acute kidney injury in the DARE-19 trial.[1] We used several definitions of kidney events in the trial, which were prespecified in the protocol approved by regulatory authorities in each participating country. The kidney organ dysfunction component of the primary efficacy endpoint of prevention included doubling of serum creatinine or initiation of renal replacement therapy during index hospitalisation; the first key secondary efficacy endpoint was a kidney composite, which also included serious adverse events of acute kidney injury after discharge and all-cause mortality until day 30; and acute kidney injury was also a key safety event (defined as doubling of serum creatinine during index hospitalisation or a serious adverse event of acute kidney injury after discharge until day 30). Regardless of the definitions used, there was no evidence for an increased risk of acute kidney injury with dapagliflozin compared with placebo. The number of kidney events was numerically lower in patients who received dapagliflozin across all these endpoints, although these findings did not reach statistical significance.

Reis and colleagues suggest that the definitions of acute kidney injury in the DARE-19 trial (which capture Kidney Disease: Improving Global Outcomes [KIDIGO] stage 2 and higher) were overly strict, and that all stages of acute kidney injury (including stage 1 acute kidney injury) should be used in the evaluation of SGLT2 inhibitors (which might cause an acute dip in estimated glomerular filtration rate) in patients hospitalised with acute COVID-19. The key argument behind this suggestion is that earlier stages of acute kidney injury are common, and have been shown to be of prognostic importance, but might have been missed because of our more restrictive definitions. We would like to point out that the prognostic implications of acute kidney injury referenced by Reis and colleagues typically refer to the incidence of hard clinical events, such as initiation of renal replacement therapy and death. The study by Chan and colleagues,[2] cited by Reis and colleagues, is a large study of acute kidney injury in patients hospitalised with COVID-19. Chan and colleagues,[3] specifically used the outcome of all-cause mortality when referring to the prognostic implications of different acute kidney injury stages. In the DARE-19 trial,[1] we observed no signal for a higher risk of renal replacement therapy, other prespecified events of organ failure, or death in patients who received dapagliflozin; and the number of these events, although not statistically different, were numerically lower in the dapagliflozin group compared with the placebo group. Thus, although inclusion of stage 1 acute kidney injury would have likely increased the number of acute kidney injury events by adding mild elevations in serum creatinine, it would have had no effect on the results of the DARE-19 trial as it pertains to the important clinical events.

In summary, we do not believe that inclusion of KIDIGO stage 1 acute kidney injury would have altered the key conclusions of the DARE-19 trial.

MNK has received a research grant for the conduct of this study from AstraZeneca. He has also received grant and research support from AstraZeneca. He has received a grant and honoraria from Boehringer-Ingelheim, and honoraria from Sanofi, Amgen, Novo Nordisk, Merck (Diabetes), Janssen,

Bayer, Novartis, Eli Lilly, and Vifor Pharma outside the submitted work. RE, JO, and SBG are employees and stockholders of AstraZeneca. RHMF reports research grants and personal fees from AstraZeneca, Bayer, and Servier; and research grants from Pfizer, EMS, Aché, Brazilian Ministry of Health, University Health Network, and Lemann Foundation Research Fellowship. SV reports receiving grants, speaker honoraria and consulting fees from Boehringer-Ingelheim, AstraZeneca, and Janssen. He has received speaker honoraria and consulting fees from Eli Lilly, and speaker honoraria from EOCI Pharmacomm, Sun Pharmaceuticals, and Toronto Knowledge Translation Working Group during the conduct of this study. He has also received grants and consulting fees from Amgen; grants, speaker honoraria and consulting fees from Bayer, and from Merck; grants from Bristol-Myers Squibb; speaker honoraria and consulting fees from HLS Therapeutics, Novo Nordisk, and Sanofi; and speaker honoraria from Novartis. OB reports grants from AstraZeneca, Novartis, Bayer, Amgen, and Boehringer-Ingelheim.

**Mikhail N Kosiborod, Russell Esterline, Jan Oscarsson, Samvel B Gasparyan, Remo H M Furtado, Subodh Verma, Otavio Berwanger*

mkosiborod@saint-lukes.org

Department of Cardiology, Saint Luke's Mid America Heart Institute, Kansas City, MO 64111, USA (MNK); Department of Medicine, University of Missouri-Kansas City, Kansas City, MO, USA (MNK); The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia (MNK); Late-stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, USA (RE); Late-stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research & Development, AstraZeneca, Gothenburg, Sweden (JO, SBG); Academic Research Organization, Hospital Israelita Albert Einstein, Sao Paulo, Brazil (RHMF, OB); Instituto do Coracao do Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil (RHMF); Division of Cardiac Surgery, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto, ON, Canada (SV); Department of Surgery and Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada (SV)

1 Kosiborod MN, Esterline R, Furtado RHM, et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Diabetes Endocrinol* 2021; **9:** 586–94.

2 Chan L, Chaudhary K, Saha A, et al. AKI in hospitalized patients with COVID-19. *J Am Soc Nephrol* 2021; **32:** 151–60.